▲ At the invitation of Chairman Yoon Seok-heon of the Korea-Iran Chamber of Commerce and Industry, the president of Vietnam's Phú Thái Group, Pam Dinh Doan, visited AdipoLABs.

(Seoul = Gukje News) Reporter Min Kyung-chan = AdipoLABs announced on the 30th that the chairman of Vietnam's Phú Thái Group, Palm Dinh Doan, visited AdipoLABs with the invitation of Chairman Yoon Suk-Hun of the Korea-Iran Chamber of Commerce and Industry.

Mr. Palm visited Korea to cooperate with promising new technology companies in Korea. Among these companies, he visited AdipoLABs because he knew the efficacy of ‘REMISSION 1 ℃’, medical high-frequency hyperthermia cancer treatment device of AdipoLABs.

Phú Thái Group was founded in 1993 in Vietnam and currently employs about 30 organizations and 3,000 employees, including its member companies, distribution centers and warehouses. The company has an impressive average annual growth rate of 40% thanks to professional manpower and management innovation.

It has also grown steadily as a proven company with many awards from the Prime Minister, the Ministry of Finance, the Ministry of Commerce, the Hanoi People's Committee, the National Union, the Vietnam Labor Party, the Hanoi Young Business Association and the Small and Medium Business Association.

Chairman Choi Ihl-bohng, Chairman of the Korea Institute of Thermal Medicine and Chairman Yoon Seok-heon, Chairman of the Korea-Iran Chamber of Commerce and Industry, attend this meeting with Phú Thái Group. AdipoLABs CEO, Han Sung-ho introduced the company's introduction, the principle of operation of REMISSION 1 ℃, and the current state of supply in Korea.

In addition, Mr. Choi gave a medical explanation on high-frequency hyperthermia therapy and immunotherapy. Regarding Vietnam distribution of ‘REMISSION 1℃’, high-frequency hyperthermia cancer treatment device developed in Korea, the explanation of the project was carried out through the guidance of Mr. Yoon, Chairman of the Korea-Iran Chamber of Commerce and Industry.

Mr. Palm, Chairman of Phú Thái Group, recognized that there would be great hope for Vietnam's cancer patients and making good image of Phú Thái Group for distribution of ‘REMISSION 1℃’, high-frequency hyperthermia cancer treatment device in Vietnam.

Since this meeting, AdipoLABs has made several proposals to Phú Thái Group, and has proposed a roadmap that embodies a business schedule that links not only treatment cancer patients but also cancer seminars with local cancer specialists in Vietnam and Korea cancer specialists.

In particular, Phú Thái Group is reviewing this very positively, and the launch of the high-frequency hyperthermia cancer treatment device, REMISSION 1 ℃, will export soon to Vietnam.

Han Sung-ho, CEO of AdipoLABs, said, ‘REMISSION 1℃’, high-frequency hyperthermia cancer treatment device developed by domestic technology is a hope for cancer patients from all around world. Therefore, he will focus on exporting to Vietnam as a bridgehead for delivering hope messages to cancer patients and their families in Vietnam too.